May 2017 FDA Recall Levophed by Hospira Inc., A Pfizer Company
D-0898-2017 - GMP Deviation; A foreign stopper was observed during packaging of a lot of product.

This Class II drug recall was voluntarily initiated by Hospira Inc., A Pfizer Company on May 18, 2017 for the product Levophed. The FDA reported the reason for recall as gmp deviation; a foreign stopper was observed during packaging of a lot of product.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0898-2017

Reason for Recall
GMP Deviation; A foreign stopper was observed during packaging of a lot of product.
Initiated
05-18-2017
Reported
06-21-2017
Quantity
(720503A): 43,200 vials, (720603A): 400 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Hospira Inc., A Pfizer Company
Nationwide, Canada and Singapore
Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc. Lake Forest, IL --- NDC 0409-3375-04

Batch or Lot Expiration Information

Lot# 720503A, 720603A (Canada only)